|Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.||CEO, Pres & Director||659.03k||N/A||1968|
|Ms. Susan Horvath||VP of Fin., CFO, Sec. & Treasurer||401.82k||N/A||1959|
|Dr. Thomas X. Neenan Ph.D.||Co-Founder & Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Tammy Groene||VP of Operations||N/A||N/A||N/A|
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Panbela Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.